Get the Stockscreener App
0.2986
4.74%
0.0135
After Hours:
.29
-0.0086
-2.88%
Leap Therapeutics Inc stock is traded at $0.2986, with a volume of 605.16K.
It is up +4.74% in the last 24 hours and down -7.67% over the past month.
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.
See More
Previous Close:
$0.2851
Open:
$0.277
24h Volume:
605.16K
Relative Volume:
0.33
Market Cap:
$12.37M
Revenue:
$1.50M
Net Income/Loss:
$-64.59M
P/E Ratio:
-0.1788
EPS:
-1.67
Net Cash Flow:
$-55.17M
1W Performance:
+5.51%
1M Performance:
-7.67%
6M Performance:
-26.18%
1Y Performance:
-89.37%
1-Day Range:
$0.277
$0.3099
1-Week Range:
$0.27
$0.3099
52-Week Range:
$0.2223
$4.79
Leap Therapeutics Inc Stock (LPTX) Company Profile
Name
Leap Therapeutics Inc
Sector
Industry
Phone
617 252 4343
Address
47 THORNDIKE STREET, CAMBRIDGE, MA
Compare LPTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LPTX
Leap Therapeutics Inc
|
0.2986 | 11.73M | 1.50M | -64.59M | -55.17M | -1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Leap Therapeutics Inc Stock (LPTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jan-29-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-28-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-04-21 | Initiated | Mizuho | Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Jun-29-20 | Initiated | Piper Sandler | Overweight |
| Feb-11-20 | Initiated | Robert W. Baird | Outperform |
| Nov-15-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Sep-13-19 | Resumed | Raymond James | Outperform |
| Mar-07-17 | Initiated | Ladenburg Thalmann | Buy |
View All
Leap Therapeutics Inc Stock (LPTX) Latest News
Leap Therapeutics Inc. stock volume spike explainedJuly 2025 Price Swings & Accurate Intraday Trading Signals - Newser
Published on: 2025-09-12 14:15:00 - Newser
Regression analysis insights on Leap Therapeutics Inc. performance2025 Market Overview & Consistent Income Trade Ideas - Newser
Is Leap Therapeutics Inc. stock poised for growthQuarterly Growth Report & Weekly High Return Opportunities - Newser
Published on: 2025-09-12 06:13:05 - Newser
Risk vs reward if holding onto Leap Therapeutics Inc.Trade Exit Summary & Entry Point Confirmation Alerts - Newser
Using RSI to spot recovery in Leap Therapeutics Inc.Earnings Growth Report & Real-Time Chart Breakout Alerts - Newser
Signal strength of Leap Therapeutics Inc. stock in tech scannersMarket Activity Summary & Breakout Confirmation Trade Signals - Newser
is leap therapeutics inc. stock poised for growth2025 Earnings Impact & High Conviction Trade Alerts - Newser
Live market analysis of Leap Therapeutics Inc.M&A Rumor & Short-Term High Return Strategies - Newser
Using fundamentals and technicals on Leap Therapeutics Inc.Trade Analysis Summary & Smart Money Movement Tracker - Newser
Is Leap Therapeutics Inc. building a consolidation baseMarket Growth Summary & High Accuracy Trade Signal Alerts - Newser
How sentiment analysis helps forecast Leap Therapeutics Inc.Quarterly Portfolio Summary & Intraday High Probability Alerts - Newser
Applying chart zones and confluence areas to Leap Therapeutics Inc.2025 Valuation Update & Reliable Volume Spike Trade Alerts - Newser
Understanding Leap Therapeutics Inc.’s price movementWeekly Profit Analysis & Reliable Volume Spike Alerts - Newser
Published on: 2025-09-11 19:11:22 - Newser
Can machine learning forecast Leap Therapeutics Inc. recoveryPortfolio Growth Summary & AI Driven Stock Reports - Newser
Leap Therapeutics Granted Extension by Nasdaq - TipRanks
Published on: 2025-09-11 14:23:28 - Newser
What recovery options are there for Leap Therapeutics Inc.Weekly Trading Summary & Daily Growth Stock Investment Tips - Newser
Is Leap Therapeutics Inc. showing signs of accumulation2025 Winners & Losers & Verified Swing Trading Watchlists - Newser
News impact scoring models applied to Leap Therapeutics Inc.July 2025 Market Mood & Scalable Portfolio Growth Ideas - Newser
Leap Therapeutics Inc. stock outlook for YEARVolume Spike & Safe Capital Growth Tips - Newser
How to escape a deep drawdown in Leap Therapeutics Inc.2025 Big Picture & Technical Entry and Exit Alerts - Newser
Chart overlay techniques for tracking Leap Therapeutics Inc.Analyst Downgrade & Stepwise Entry and Exit Trade Signals - Newser
What earnings revisions data tells us about Leap Therapeutics Inc.Weekly Market Report & Accurate Intraday Trading Signals - Newser
Is Leap Therapeutics Inc. forming a reversal patternMarket Growth Summary & Technical Pattern Based Signals - Newser
Will a bounce in Leap Therapeutics Inc. offer an exitQuarterly Investment Review & Community Trade Idea Sharing - Newser
understanding leap therapeutics inc.’s price movementMarket Growth Summary & Consistent Profit Focused Trading Strategies - Newser
Leap Therapeutics Inc. Recovery Gathers Momentum on Chart SignalsJuly 2025 Highlights & Smart Investment Allocation Tips - beatles.ru
Leap Therapeutics Inc Stock (LPTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):